Syngene confirms expansion of biologics facility with new ADC bioconjugation capability

The new suite of capabilities will accelerate development timelines by enabling both monoclonal antibody (mAb) production and GMP bioconjugation at a single site. Shares of Syngene International Ltd ended at ₹661.10, up by ₹19.25, or 3.00%, on the BSE.

Source link